Hybrid LT-A/CT-B holotoxin for use as an adjuvant

Details Hybrid LT-A/CT-B holotoxin for use as an adjuvant Hybrid LT-A/CT-B holotoxin for use as an adjuvant

2006-06-20

2006-06-20

Graser, Jennifer E. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Combination of antigens from multiple bacterial species

C424S236100, C424S235100, C424S257100, C424S261100, C424S193100, C424S197110, C530S350000

Reexamination Certificate

active

07063852

ABSTRACT:
The present invention provides a novel composition which is a hybrid heat labile enterotoxin comprising the A-subunit of the heat labile toxin ofEscherichia coli(LT-A) and the B-subunit of the cholera enterotoxin ofVibrio cholerae(CT-B). The hybrid toxin is designated LT-A/CT-B. The LT-A subunit, the CT-B subunit, or both subunits of the hybrid toxin may be mutant subunits, e.g., differing from wild-type subunits by amino acid substitutions, deletions or additions. Also provided are methods of using the novel LT-A/CT-B comprising compositions of the invention as adjuvants for vaccines, methods of making the LT-A/CT-B hybrid holotoxin, and kits.

REFERENCES:
patent: 4328209 (1982-05-01), Finkelstein et al.
patent: 6019973 (2000-02-01), Holmgren et al.
patent: 6149919 (2000-11-01), Domenighini et al.
patent: 2217600 (1989-11-01), None
patent: WO 92/19265 (1992-11-01), None
patent: WO 93/13202 (1993-07-01), None
patent: WO 95/17211 (1995-06-01), None
Takeda et al. Infect. Immun. 1981. 34(2):341-6.
Rodighiero et al. 1998. Biochem. Soc. Trans. 26(4):S364.
Häse et al., 1994, “Construction and characterization of recombinantVibrio choleraestrains producing inactive cholera toxin analogs”, Infect. Immun. 62(8):3051-3057.
McGhee et al., 1994, “Vaccines for mucosal immunity: Unique delivery system and immune response analyses for Th1/TH2 cells and IgE/IgA B cells”, Mucosal Immunology Update, Spring 1994, Raven Press, New York p. 21.
Moss et al., 1993, “Interaction of ADP-ribosylation factor withEscherichia colienterotoxin that contains an inactivating lysine 112 substitution”, J. Biol. Chem. 268(9):6383-6387.
Conner et al., 1993, “Rotavirus vaccine administered parenterally induces protective immunity”, J. Virol. 67(11):6633-6641.
Santiago et al., 1993, “Oral immunization of rats with proteinoid microspheres encapsulating influenza virus antigens”, Pharmaceutical Research 10(8):1243-1247.
Gould-Fogerite and Mannino, 1993, In: Liposome Technology, Second Edition, vol. III, Gregoriadis (ed.), CRC Press, Boca Raton pp. 261-276.
Clements et al., 1992, In: Recombinant DNA vaccines: Rationale and Strategy, Isaacson (ed.), Marcel Decker, New York pp. 293-321.
Cardenas and Clements, 1992, “Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens”, Clin. Microbiol. Rev. 5(3):328-342.
Lycke et al., 1992, “The adjuvant effect of Vibrio cholerae andEscherichia coliheat-labile enterotoxins is linked to their ADP-ribosyltransferase activity”, Eur. J. Immunol. 22:2277-2281.
Garcon and Six, 1991, “Universal vaccine carrier: Liposomes that provide T-dependent help to weak antigens”, J. Immunol. 146:3697-3702.
Clements and Cardenas, 1990, “Vaccines against enterotoxigenic bacterial pathogens based on hybridSalmonellathat express heterologous antigens”, Res. Microbiol. 141:981-993.
Brandtzaeg, 1989, “Overview of the mucosal immune system”, Curr. Top. Microbiol. Immunol. 146:13-25.
Elson, 1989, “Cholera toxin and its subunits as potential oral adjuvants”, Curr. Topics Microbiol. Immunol. 146:29-33.
Liang et al., 1988, “Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus”, J. Immunol. 141(5):1495-1501.
Clemens et al., 1988, “Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenicEscherichia coli: Results of a large-scale field trial”, J. Infect. Dis. 158(2):372-377.
Clements et al., 1988, “Adjuvant activity ofEscherichia coliheat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens”, Vaccine 6:269-277.
Clements et al., 1988, “Escherichia coliheat-labile enterotoxin possesses adjuvant activity and prevents the induction of oral tolerance in mice to unrelated protein antigens”, Abstract No. B-91, 88th Ann. Meet. Am. Soc. Microbiol.
Alving et al., 1986, “Effectiveness of liposomes as potential carriers of vaccines: Applications to cholera toxin and human malaria sporozoite antigen”, Vaccine 4:166-172.
Owen et al., 1986, “M cell transport ofVibrio choleraefrom the intestinal lumen into Peyer's patches: A mechanism for antigen sampling and for microbial transepithelial migration”, J. Infect. Dis. 153(6):1108-1118.
Lycke and Holmgren, 1986, “Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens”, Immunology 59:301-308.
Cebra et al., 1986, In: Vaccines 86, Brown et al. (eds.), Cold Spring HArbor Laboratory, New York pp. 129-133.
Elson and Ealding, 1984, “Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen”, J. Immunol. 133(6):2892-2897.
Clements and El-Morshidy, 1984, “Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas”, Infect. Immun. 46(2):564-569.
Strober and Jacobs, 1985, In: Advances in host defense mechanisms, vol. 4., Mucosal Immunity, Gallin and Fauci (eds.), Raven Press, New York, pp. 1-30.
Tomasi and Plaut, 1985, In: Advances in host defense mechanisms, vol. 4, Mucosal Immunity, Gallin and Fauci (eds.), Raven Press, New York, pp. 31-61.
McKenzie and Halsey, 1984, Cholera toxin B subunit as a carrier protein to stimulate mucosal immune response, J. Immunol. 133(4):1818-1824.
Elson and Ealding, 1984, “Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin”, J. Immunol. 132(6):2736-2741.
Svennerholm et al., 1984, “Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine”, J. Infect. Dis. 149(6):884-893.
Pierce et al., 1983, “Procholeragenoid: A safe and effective antigen for oral immunization against experimental cholera”, Infect. Immun. 40(3):1112-1118.
Clements et al., 1983, “Cloning and molecular characterization of the B subunit ofEscherichia coliheat-labile enterotoxin”, Infect. Immun. 40:653-658.
Dallas and Falkow, 1980, “Amino acid sequence homology between cholera toxin andEscherichia coliheat-labile toxin”, Nature 288:499-501.
Clements et al., 1980, “Properties of homogenous heat-labile enterotoxin fromEscherichia coli”, Infect. Immun. 29:91-97.
Field, 1980, In: Secretory diarrhea, Field et al., (eds.) Waverly Press, Baltimore, pp. 21-30.
Clements and Finkelstein, 1979, “Isolation and characterization of homogenous heat-labile enterotoxins with high specific activity fromEscherichia colicultures”, Infect. Immun. 24:760-769.
Clements and Finkelstein, 1979, “Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae andEscherichia coli”, Infect. Immun. 22:709-713.
Clements and Finkelstein, 1978, “Immunological cross-reactivity between a heat-labile enterotoxin(s) ofEscherichia coliand subunits of Vibrio cholerae enterotoxin”, Infect. Immun. 21:1036-1039.
Finkelstein, 1975, “Immunology of cholera”, Curr. Top. Microbiol. Immunol. 69:139-196.
Bockman and Cooper, 1973, “Pinocytosis by epithelium associated with lymphoid follicles in the bursa of fabricius, appendix, choleragenoid”, J. Exp. Med. 130:185-202.
Douce et al., 1995, “Mutants ofEscherichia coliheat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants”, Proc Natl Acad Sci 92:1644-1648.
Lobet et al., 1991, “Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit ofEscherichia coliheat-labile enterotoxin”, Infection and Immunity 59(9):2870-2879.
Burnette et al., 1991, “Site-specific mutagenesis of the catalytic subunit of cholera toxin: Subst

Affiliated with

Also associated with

Rating

Hybrid LT-A/CT-B holotoxin for use as an adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybrid LT-A/CT-B holotoxin for use as an adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid LT-A/CT-B holotoxin for use as an adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3677927